Torgarzo Physician

LIGHTEN THE LOAD

LIGHTEN THEIR VIRAL LOAD, AND MAKE UNDETECTABLE A POSSIBILITY AGAIN

TROGARZO® (ibalizumab-uiyk) offers powerful, durable virological response for HIV-1 patients with second-line regimen failure, and beyond.1,2

EXPLORE CLINICAL EFFICACY DATA

A POWERFUL
VIROLOGIC RESPONSE

AT 7 DAYS POST-LOADING DOSE

(TROGARZO® functional monotherapy): 83% of patients achieved a virologic response vs. 3% of patients pre-loading dose (p < 0.0001; 95% CI: 67%, 93%).

A DURABLE
VIROLOGIC RESPONSE

PATIENTS WHO ACHIEVED HIV RNA < 50 COPIES/ML AT WEEK 24 MAINTAINED VIRAL SUPPRESSION UP TO WEEK 48.

TROGARZO® IS INCLUDED IN THE DHHS GUIDELINES.

Find Out Why

ITT-MEF = Intent To Treat - Missing Equals Failure.

A single arm, multicenter study of 40 heavily treatment-experienced patients with multidrug resistant HIV-1. Patients were required to have viral load >1,000 copies/mL, documented resistance to at least 1 antiretroviral from each of 3 classes of antiretrovirals, been treated for at least 6 months and be failing or had recently failed therapy. Days 0-6 (Control period): Patients were monitored on their current failing regimens (or no therapy). Days 7-13 (Functional monotherapy period): Patients continued on background failing regimens and received 2,000 mg of TROGARZO® (loading dose). Day 14: Background regimen was optimized to include at least one active agent. Day 21-Week 25 (Maintenance period): Patients received 800 mg of TROGARZO® every 2 weeks (maintenance dose). The primary efficacy endpoint was the proportion of patients achieving a –0.5 log10 decrease in viral load during the Functional monotherapy period, as compared to the proportion of patients achieving a –0.5 log10 decrease during the Control period.